Stallergenes Articles
Stallergenes and DBV Technologies partner on developing novel respiratory allergies treatments
20 May 2013
Stallergenes adds France to roll-out of grass pollen therapy Oralair
22 November 2012
Ares Life Sciences aims to take full control of Stallergenes, having already bought Wendel’s 46% stake in the firm
18 November 2010
France’s Stallergenes licenses two allergens to Japan’s Shionogi for up to 70 million euros
8 September 2010
Showing 1-5 of 5 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
